The poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor veliparib plus platinum-based chemotherapy for induction therapy, followed by maintenance therapy with veliparib, improves progression-free survival (PFS) in the initial treatment of high-grade serous ovarian carcinoma, according to a study published online Sept. 28 in the New England Journal of Medicine.
The researchers found that among women with a BRCA mutation, the median PFS was 34.7 months in the veliparib-throughout group and 22.0 months in the control group (hazard ratio for progression or death, 0.44). Among patients with homologous-recombination deficiency, the corresponding values for PFS were 31.9 and 20.5 months, respectively (hazard ratio, 0.57). In the intention-to-treat population, the corresponding values for PFS were 23.5 and 17.3 months, respectively (hazard ratio, 0.68). There were higher incidences of anemia and thrombocytopenia when veliparib was combined with chemotherapy.
“These results further validate the role of this class of drug in the treatment of patients with ovarian cancer and offer a new therapeutic asset that can be initiated with the start of their adjuvant chemotherapy treatment,” Coleman said in a statement.
